Catalyst Biosciences Stock price

Equities

CBIO

US14888D2080

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
17.53 USD +4.41% Intraday chart for Catalyst Biosciences -1.85% +128.57%
Sales 2021 7.34M Sales 2022 794K Capitalization 16.61M
Net income 2021 -87M Net income 2022 -8M EV / Sales 2021 -2.15 x
Net cash position 2021 44.47M Net cash position 2022 21.63M EV / Sales 2022 -6.32 x
P/E ratio 2021
-0.32 x
P/E ratio 2022
-2.02 x
Employees 7
Yield 2021 *
-
Yield 2022
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Catalyst Biosciences, Inc.(NasdaqCM:CBIO) dropped from NASDAQ Composite Index CI
Beijing Continent Pharmaceutical Co., Ltd. completed the acquisition of Catalyst Biosciences, Inc. in a reverse merger transaction. CI
Catalyst Biosciences, Inc. announced that it has received $4.999815 million in funding from GNI USA, Inc. CI
Catalyst Biosciences, Inc. announced that it expects to receive $4.999815 million in funding from GNI USA, Inc. CI
Catalyst Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Catalyst Biosciences, Inc. has Changed its Name to Gyre Therapeutics, Inc CI
North American Morning Briefing : China Trouble Hits Sentiment DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Catalyst Biosciences Files Registration Statement on Behalf of Selling Stockholders MT
Catalyst Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
North American Morning Briefing : Hopes Build for -3- DJ
Catalyst Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
North American Morning Briefing : Stocks Seen -2- DJ
Catalyst Biosciences, Inc. Auditor Raises 'Going Concern' Doubt CI
GC Biopharma Takes Over Catalyst Biosciences' Orphan Hematology Disorder Treatment Candidates MT
More news
1 day+4.41%
Current month+128.57%
6 months+138.50%
Current year+128.57%
More quotes
1 year
2.85
Extreme 2.85
17.93
3 years
2.83
Extreme 2.8305
82.03
5 years
2.83
Extreme 2.8305
162.60
10 years
2.83
Extreme 2.8305
4 860.00
More quotes
Date Price Change Volume
24-03-27 17.53 +4.41% 71,488
24-03-26 16.79 +3.77% 68,093
24-03-25 16.18 -8.02% 39,744
24-03-22 17.59 -1.24% 26,356
24-03-21 17.81 -0.28% 37,031

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Catalyst Biosciences, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of Hydronidone for the treatment of nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease in the United States. Hydronidone is being evaluated for the treatment of liver fibrosis associated with a spectrum of chronic liver diseases. A Phase 1 clinical trial of Hydronidone has been completed in the United States and generated pharmacokinetic (PK), safety and tolerability data of single and multiple ascending doses of Hydronidone in United States healthy subjects. Hydronidone is a structural analogue of the approved anti-fibrotic (pulmonary fibrosis) drug pirfenidone. Hydronidone has been shown to inhibit both p38y kinase activity and TGF-b1- induced excessive collagen synthesis in vitro in hepatic stellate cells (HSCs), which are recognized as critical events in the development and progression of fibrosis in the liver.
Sector
-
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock
  2. Equities
  3. Stock Catalyst Biosciences - Nasdaq